Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFC Albuterol Inhaler Phase-Out Urged By Nine Groups In Citizen Petition

Executive Summary

Removing CFC-containing albuterol metered-dose inhalers from the essential use list would increase certainty about medication supply while providing asthma patients an adequate transition period to non-CFC alternatives, professional and patient groups said in a citizen petition to FDA

You may also be interested in...



FDA 2004 Reg Agenda Includes CFC Albuterol Phase Out, Final Label Rule

FDA will begin the phase out of CFC-containing albuterol products during 2004, according to HHS' semiannual regulatory agenda published in the Dec. 22 Federal Register

FDA 2004 Reg Agenda Includes CFC Albuterol Phase Out, Final Label Rule

FDA will begin the phase out of CFC-containing albuterol products during 2004, according to HHS' semiannual regulatory agenda published in the Dec. 22 Federal Register

CFC-Containing Albuterol Phase-Out Review To Begin January 2003

FDA will begin the phase-out process for CFC-containing albuterol and beclomethasone products after Jan. 20, 2003, when its final rule on ozone-depleting substances goes into effect

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel